NCT04652765

Camostat With Bicalutamide for COVID-19

COMBO Trial: Camostat With Bicalutamide for COVID-19

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This will be a randomized, open-label study to determine if camostat+ bicalutamide decreases the proportion of people with COVID-19 who require hospitalization, compared to historical controls. Patients with symptomatic COVID-19, diagnosed as outpatients, will be randomized 1:1, stratified by gender, to treatment with standard of care alone (Arm 1) or with camostat and bicalutamide (Arm 2).

Conditions

• Covid19
• SARS-CoV Infection
• Coronavirus Infection

Interventions

Type	Name	Description
DRUG	Camostat Mesilate	Camostat 600mg by mouth four times a day, for a total of 7 days
DRUG	Bicalutamide 150 mg	Bicalutamide 150mg by mouth once daily, for a total of 7 days

Timeline

• Start date: 2021-02-03
• Primary completion: 2021-09-15
• Completion: 2021-09-15
• First posted: 2020-12-03
• Last updated: 2023-10-06
• Results posted: 2023-10-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study